55 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
29 Jan 24
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
7:05am
safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis
PETACH TIKVA, Israel, January 29
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
20 Dec 23
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030
7:09am
between chronic diseases and obesity. The World Health Organization reports that obesity has nearly tripled since 1975 and at least 2.8 million people
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
18 Dec 23
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
7:07am
patients due to Piclidenoson’s good safety profile
There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis … will enable Can-Fite to position Piclidenoson with its favorable safety and good efficacy as a treatment for this chronic and devastating disease.
Can-Fite
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
18 Aug 23
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
7:06am
, and effective drugs to treat chronic plaque psoriasis in the adolescents
PETACH TIKVA, Israel, August 18, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF … efficacy as a treatment for this chronic and devastating disease.
Can-Fite believes the inclusion of adolescent patients in one or both of the Phase 3
6-K
EX-99.1
adqpk4lgt05hg
29 Jun 23
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
7:10am
6-K
EX-99.1
zz35 j9uht5x
10 Apr 23
Report of Foreign Private Issuer
7:06am
6-K
EX-99.1
339j7
25 Nov 22
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
7:12am
6-K
EX-99.1
ux1dhw nkx3t3p7
12 Sep 22
Report of Foreign Private Issuer
7:02am
6-K
EX-99.1
uhw zg2403ztiq
29 Jun 22
Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORTTM Study in Moderate to Severe Psoriasis
7:09am
6-K
EX-99.1
xae 152p7
9 Jun 22
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
7:03am
6-K
EX-99.1
rph9bf hipzmpfz8xuco
23 Nov 21
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
7:22am
6-K
EX-99.1
wvp4z
2 Sep 21
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
7:17am
6-K
EX-99.1
wl723vo 2b
13 Oct 20
Key Opinion Leader in the Treatment of Psoriasis to Join the Presentation and Q&A
7:08am
6-K
EX-99.1
1x8ekarn fitrfkc1qu8
30 Jun 20
Report of Foreign Private Issuer
7:07am
424B3
16ljsf
7 Apr 20
Prospectus supplement
4:33pm
6-K
EX-99.1
y0hhrcptuf jz51
7 Apr 20
Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
9:11am